breast cancer

Cancer Drugs Targeting IDO1 And Approved Antibody Kisunla Offer Separate Paths For People Facing Early Alzheimer’s Disease
Health News

Cancer Drugs Targeting IDO1 And Approved Antibody Kisunla Offer Separate Paths For People Facing Early Alzheimer’s Disease

Eli Lilly's Kisunla won FDA approval on July 2, 2024, an EU authorization in September 2025, and a slower-titration label in July 2025 that cut ARIA-E. A 2024 Science paper…
Pulsante per tornare all'inizio